VKTX revenueQ3 2026$0
VKTX revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Viking Therapeutics Inc. (VKTX) financials
For the twelve months ended Sep 30, 2026, Viking Therapeutics Inc. reported $0 of revenue and -$627.20M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$627.20M
- EPS, diluted, TTM
- -$5.41
- Cash
- $677.61M
- Total debt
- $250.66M
- Market cap
- $3.52B
FY2016FY2025
FY2016FY2025
VKTX revenue and earnings growth
VKTX net incomeQ3 2026-$183.19M
VKTX net income was -$183.19M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$90.79M a year earlier. For the full fiscal 2025 it was -$359.64M, compared with -$109.96M in fiscal 2024.
VKTX EPSQ3 2026-$1.55
VKTX diluted EPS was -$1.55 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.81 a year earlier. For the full fiscal 2025 it was -$3.19, compared with -$1.01 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $344.95M | $101.64M | $63.81M | $54.23M | $44.98M | $31.93M | $23.56M | $19.04M | $13.74M | $9.00M |
| Selling, general and admin | $48.39M | $49.28M | $37.02M | $16.12M | $10.70M | $10.73M | $9.13M | $7.12M | $5.33M | $4.85M |
| Operating income | -$393.34M | -$150.92M | -$100.83M | -$70.36M | -$55.68M | -$42.66M | -$32.69M | -$26.16M | -$19.07M | -$13.85M |
| Pre-tax income | -$359.64M | -$109.96M | -$85.89M | - | - | - | - | - | - | - |
| Income tax | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$359.64M | -$109.96M | -$85.89M | -$68.87M | -$54.99M | -$39.49M | -$25.78M | -$22.06M | -$20.58M | -$14.73M |
| EPS, basic | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | -$0.54 | -$0.36 | -$0.38 | -$0.79 | -$0.90 |
| EPS, diluted | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | -$0.54 | -$0.36 | -$0.38 | -$0.79 | -$0.90 |
| Diluted shares | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 72.6M | 72.0M | 57.6M | 26.0M | 16.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.81M | $26.68M | $55.52M | $36.63M | $26.37M | $29.12M | $8.38M | $24.78M | $8.99M | $3.08M |
| Current assets | $715.60M | $907.22M | $367.23M | $167.04M | $210.53M | $256.10M | $283.50M | $302.13M | $21.85M | $13.97M |
| Total assets | $715.73M | $908.32M | $368.49M | $168.53M | $210.66M | $256.50M | $284.26M | $302.31M | $22.12M | $14.54M |
| Current liabilities | $76.67M | $27.41M | $19.14M | $21.95M | $8.78M | $12.13M | $6.78M | $4.55M | $8.66M | $6.48M |
| Long-term debt | $0 | - | - | - | - | - | - | - | - | - |
| Total debt | $0 | - | - | - | - | - | - | - | - | - |
| Total liabilities | $76.67M | $28.04M | $20.07M | $23.21M | $8.78M | $12.16M | $7.14M | $4.56M | $8.66M | $6.49M |
| Shareholders' equity | $639.06M | $880.28M | $348.42M | $145.32M | $201.88M | $244.34M | $277.12M | $297.75M | $13.46M | $8.04M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$278.69M | -$87.79M | -$73.38M | -$48.40M | -$47.59M | -$21.78M | -$24.75M | -$18.75M | -$14.76M | -$11.07M |
| Investing cash flow | $341.39M | -$553.37M | -$179.09M | $54.75M | $37.96M | $41.57M | $7.46M | -$265.73M | -$1.73M | $3.03M |
| Financing cash flow | $76.44M | $612.46M | $271.38M | $4.16M | $6.88M | $950.0K | $887.0K | $300.27M | $22.40M | $10.35M |
| Share repurchases | - | - | - | $6.79M | - | - | - | - | - | $229 |
| Stock-based compensation | $40.82M | $29.71M | $16.75M | $8.67M | $6.10M | $5.82M | $3.74M | $2.61M | $1.45M | $1.79M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -56.3% | -12.5% | -24.7% | -47.4% | -27.2% | -16.2% | -9.3% | -7.4% | -152.8% | -183.2% |
| Return on assets | -50.2% | -12.1% | -23.3% | -40.9% | -26.1% | -15.4% | -9.1% | -7.3% | -93.0% | -101.3% |
| Current ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.12 | 41.83 | 66.40 | 2.52 | 2.16 |
| Debt to equity | 0.00 | - | - | - | - | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $166.80M | $115.75M | $150.15M | $153.46M | $89.95M | $60.15M | $41.39M | $30.99M | $22.79M | $23.77M | $24.10M | $20.50M |
| Selling, general and admin | $20.31M | $16.84M | $13.97M | $11.28M | $8.61M | $14.42M | $14.08M | $15.25M | $13.77M | $10.29M | $9.97M | $8.78M |
| Operating income | -$187.11M | -$132.60M | -$164.13M | -$164.74M | -$98.56M | -$74.57M | -$55.47M | -$46.24M | -$36.56M | -$34.05M | -$34.07M | -$29.29M |
| Interest expense | $88.0K | - | - | - | $0 | - | - | - | - | - | - | - |
| Net income | -$183.19M | -$128.02M | -$158.32M | -$157.66M | -$90.79M | -$65.56M | -$45.63M | -$35.42M | -$24.94M | -$22.25M | -$27.36M | -$24.61M |
| EPS, basic | -$1.55 | -$1.10 | -$1.37 | -$1.39 | -$0.81 | -$0.58 | -$0.41 | -$0.33 | -$0.22 | -$0.20 | -$0.26 | - |
| EPS, diluted | -$1.55 | -$1.10 | -$1.37 | -$1.39 | -$0.81 | -$0.58 | -$0.41 | -$0.33 | -$0.22 | -$0.20 | -$0.26 | - |
| Diluted shares | 118.0M | 116.3M | 115.6M | - | 112.3M | 112.1M | 112.1M | - | 110.9M | 110.4M | 103.5M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $677.61M | $125.75M | $118.12M | $165.81M | $100.38M | $33.88M | $37.94M | $26.68M | $50.35M | $43.91M | $195.58M | $55.52M |
| Current assets | $973.00M | $517.56M | $608.21M | $715.60M | $738.70M | $827.02M | $866.02M | $907.22M | $936.65M | $945.72M | $966.34M | $367.23M |
| Total assets | $977.17M | $521.90M | $608.24M | $715.73M | $739.41M | $827.85M | $866.99M | $908.32M | $937.89M | $946.84M | $967.52M | $368.49M |
| Current liabilities | $133.90M | $109.66M | $106.33M | $76.67M | $26.07M | $31.98M | $19.57M | $27.41M | $25.68M | $25.09M | $32.77M | $19.14M |
| Long-term debt | $250.66M | - | - | $0 | - | - | - | - | - | - | - | - |
| Total debt | $250.66M | - | - | $0 | - | - | - | - | - | - | - | - |
| Total liabilities | $388.57M | $113.58M | $106.33M | $76.67M | $26.39M | $32.39M | $20.07M | $28.04M | $26.44M | $25.86M | $33.63M | $20.07M |
| Shareholders' equity | $588.60M | $408.32M | $501.92M | $639.06M | $713.03M | $795.46M | $846.92M | $880.28M | $911.45M | $920.98M | $933.89M | $348.42M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$138.19M | -$125.17M | -$113.98M | -$85.29M | -$94.00M | -$47.06M | -$52.33M | -$31.18M | -$21.96M | -$28.51M | -$6.13M | -$17.64M |
| Investing cash flow | $92.52M | $109.43M | $54.19M | $75.61M | $160.03M | $42.51M | $63.24M | $6.58M | $25.90M | -$126.06M | -$459.79M | $35.73M |
| Financing cash flow | $597.55M | $23.59M | $12.08M | $75.10M | $480.0K | $507.0K | $349.0K | $1.00M | $2.52M | $2.90M | $606.04M | $188.0K |
| Stock-based compensation | $17.89M | $11.13M | $10.34M | $8.59M | $7.34M | $13.55M | $11.35M | $5.67M | $8.98M | $7.08M | $7.98M | $4.08M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.27 | 4.72 | 5.72 | 9.33 | 28.34 | 25.86 | 44.25 | 33.09 | 36.47 | 37.69 | 29.48 | 19.19 |
| Debt to equity | 0.43 | - | - | 0.00 | - | - | - | - | - | - | - | - |
Source: XBRL data Viking Therapeutics Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
VKTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VKTX | $0 | - | -$627.20M | - | $3.52B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.00B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.34T |
| MDGL | $1.43B | +92.8% | -$155.46M | -10.9% | $9.88B |
VKTX FAQ
6 questionsWhat is VKTX revenue?
Viking Therapeutics Inc. (VKTX) reported $0 of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $0.Is VKTX profitable?
No. Viking Therapeutics Inc. reported a net loss of $627.20M for the twelve months ended Sep 30, 2026.How much cash and debt does VKTX have?
Viking Therapeutics Inc. reported $677.61M in cash and cash equivalents and $250.66M of debt on its most recent balance sheet in SEC filings.What is VKTX earnings per share?
Diluted earnings per share were -$5.41 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did VKTX last report financial results?
The latest statements here come from Viking Therapeutics Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.Where does this VKTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Viking Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.